Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Working Capital Changes (2020 - 2025)

Xeris Biopharma Holdings' Other Working Capital Changes history spans 6 years, with the latest figure at -$1.3 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes fell 344.33% year-over-year to -$1.3 million, compared with a TTM value of $2.1 million through Dec 2025, up 94.17%, and an annual FY2025 reading of $2.1 million, up 94.17% over the prior year.
  • Other Working Capital Changes for Q4 2025 was -$1.3 million at Xeris Biopharma Holdings, down from $4.1 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $7.5 million in Q3 2023, with the low at -$6.3 million in Q4 2023.
  • Average Other Working Capital Changes over 5 years is -$43250.0, with a median of $8000.0 recorded in 2024.
  • Year-over-year, Other Working Capital Changes plummeted 603.56% in 2023 and then soared 1273.15% in 2025.
  • Tracing XERS's Other Working Capital Changes over 5 years: stood at -$3.3 million in 2021, then surged by 72.67% to -$899000.0 in 2022, then plummeted by 603.56% to -$6.3 million in 2023, then surged by 95.54% to -$282000.0 in 2024, then tumbled by 344.33% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Other Working Capital Changes are -$1.3 million (Q4 2025), $4.1 million (Q3 2025), and $791000.0 (Q2 2025).